15 - 16 June 2026
Estrel Congress Centre, Berlin, Germany
D&D Look Back Icon

Discovery & Development Europe 2025

The European Edition Has Now Concluded
But The Journey Continues

 Next Stop: San Diego, CA | October 02 - 03, 2025

Hear From 2025's Event Moderator

Mirko Bischofberger Founder, Science Studios

After welcoming attendees and kicking off the event, Mirko Bischofberger joined us for an interview to talk about what’s happening in the discovery and development industry—offering his take on what's shaping the future.

Lights, Camera, Action!

Explore our curated photo gallery of standout moments from Discovery & Development Europe. See if you can spot yourself!

Gala Dinner: A Night of Celebration

An evening of connection, recognition, and great conversation.

Our Frontiers of Success Gala Dinner brought together attendees for a relaxed evening of networking and celebration. Guests enjoyed a three-course meal and opening remarks from Philippe Marc of Novartis, honouring the achievements driving progress in drug discovery and development.

DSC08066

NextGen Biomed 2025

Advancing Therapeutic Innovation Through Multi-Omics Research  

NextGen Omics & Spatial Biology connects thought leaders, researchers, and experts with pharmaceutical & biotech representatives to discuss the latest innovations across the fields of multi-omics. 

There are three dedicated programmes running across two full days, which together will explore multi-omics from technological development to therapeutic applications and analysis, making this a must-attend event for anyone working in clinical diagnostics, single cell & spatial biology. 

Hear from past attendees of last year's Biologics 2024 conference

Explore the NextGen Omics & Spatial Biology US 2025 Programme

Antibody Society

NextGen Biomed 2025 is supported by our
Scientific Programme Partner The Antibody Society

Discovery & Development Europe 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration in Drug Discovery, Formulation and Delivery including: 

Drug Discovery & Automation Programme - Key Themes

Panel Discussion: Technological Advancements For Novel Target Discovery

  • Application of new technologies in identifying therapeutics for novel or currently undruggable targets
  • Utilising AI/ML
  • Challenges & future opportunities

 

Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

 

•    Optimising Hit discovery
•    Minimising false positives
•    Integration of techniques

 

Moderated by Jonathan Hopper, Vice President Platforms & Founder, OMass Therapeutics

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

 

  • Emerging technologies & techniques
  • Cross-sector partnership
  • Open innovation

 

Moderated by Alexander Natz, Secretary General, EUCOPE & panellists from Cicio Holdings, BioAge Labs, European Commission, Pfizer & Business Region Gothenburg

Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea

 

  • How research leaders identify and support fundable biotech innovations
  • Overcoming early-stage funding gaps in biotech startups
  • The role of research partnerships with pharma, VCs, and industry in startup success
  • What startups can learn from research-backed biotech wins

 


Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK 

Fireside Chat: Impact of AI & Big Data in Drug Discovery & Development

 

Panel Discussion: Translational Studies to Support Better Drug Design

  • Bridging the gap between pre-clinical & clinical research
  • Biomarkers & AI/ML in translational research

 

Moderated by Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research


•    Pharma, biotech & academic partnerships
•    The need for innovation, data & technology in CNS research
•    Challenges to be solved through collaboration 

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London


Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

  • Beyond blood-based biomarkers?
  • Are we any closer to a solution?
  • Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now? 


•    Impact of automation 
•    AI/ML  
•    Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Panellists include: James Love, Vice President Cross Modalities Workflows, Novo Nordisk, Sarah Trice, COO & Head of US Operations, XtalPi & Tom Kissling, pRED Lab Automation Partner, Roche

Day 2 Breakfast Workshop: SiLA & AnIML Splash


•    Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets 
•    Feel free to bring an instrument or your own data

Formulation and Delivery Programme - Key Themes

Panel Discussion: Moving Beyond Oral Delivery

 

•    Nanoparticles
•    Inhalation
•    Transdermal
•    Developments with Oral Delivery

Moderated by Sandor Batkai, Life Science Consultant, Former, Head of Medical Research and Intelligence, Cardior Pharmaceuticals

 

Panellists include:
• Moein Moghimi, Professor of Nanomedicine & Pharmaceutics, School of Pharmacy at Newcastle University 
• Kamalinder Singh, Professor of Pharmaceutical, Technology & Drug Delivery
• Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg

Panel Discussion: Developing New Biotherapeutic Modalities While Ensuring Robustness And Quality In Their Formulations

  • Improve the stability profile of biomolecules
  • New excipients
  • Impact on product quality and stability
  • Alternative ways of formulation

 

Moderated by Amardeep Bhalla, Executive Director, Regeneron

 

Panellists Include: 

• Ramesh Kashi, Former Senior Scientific Director, Bristol-Myers Squibb
• Tanvir Tabish, Director, Early Formulation Development, AstraZeneca
• Jack Palmer, Field Application Scientist, Advanced Instruments
• Martinus Capelle, Scientific Director, Head of Process & Delivery, Johnson & Johnson Innovative Medicine

Roundtable: Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where Are We Now?

  • Challenges of drug delivery across the BBB
  • Advances in nucleic acid brain therapies
  • Future technologies and translational strategies

 

Moderated by Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group and Moein Moghimi, Professor of Nanomedicine & Pharmaceutics, School of Pharmacy at Newcastle University

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Discovery & Development Europe 2025: 23 - 24 June 2025, Basel, Switzerland

Andreas Gryczke
Director, Process Engineering,
AbbVie
Emma Mead
Chief Scientific Officer, Oxford Drug Discovery Institute,
University of Oxford
Heinrich Haas
Chief Technology Officer,
Neovacs
Karin Conde-Knape
Senior Vice President, Early Development,
Novo Nordisk
Morten Grunnet
Vice President, Head of Neuroscience ,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Shadi Farhangrazi
Chief Executive Officer,
S.M. Discovery Group
Sorina Morar-Mitrica
Director Science & Technology,,
Novartis
Stephen Pham
Senior Vice President, Product Development,
Avalyn Pharma Inc.
Ulrich Betz
Senior Vice President Innovation,
Merck
Aaron Smith
Associate Director,
AstraZeneca
Abhishek Choudhary
Principal Data Engineer,
Bayer
Abi Heath
Patent Attorney & Counsel,
Kilburn & Strode
Alain Martelli
External Science Lead Europe, Discovery Network,
Pfizer
Alex Alderton
Senior Director of High Throughput Screening,
AstraZeneca
Amal Ali Elkordy
Professor,
University of Sunderland
Amardeep Singh Bhalla
Executive Director,
Regeneron
Andreas Bernkop Schnurch
Professor,
University of Innsbruck
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Andy Pike
DMPK Project Lead,
AstraZeneca
Antonia Stepan
Section Head - Medicinal Chemistry,
Roche
April Woulfe
Scientist,
Alchemab Theraputics Ltd
Arianna Sabò
Head of Research & Discovery,
QUANTRO Therapeutics
Arne Skerra
Professor ,
Technische Universität München
Benedict Cross
CTO,
PhoreMost Ltd
Burkhard Schäfer
Managing Director & Director at SiLA,
SiLA
Cesare Spadoni
Co-Founder & Chief Operating Officer,
Oncoheroes Biosciences
Christine Maurer
Scientific Associate Director Biotransformation,
Merck Healthcare KGaA
Christoph Rösli
Director Research,
CSL Behring & BaseLaunch
Chuang Kee Ong
Director Data Product,
GSK
Cornelis Van Tilburg
Head of KiTZ CTU,
Hopp-Kindertumorzentrum Heidelberg
Covadonga Paneda
Chief Operating Officer,
Altamira Therapeutics
Daniel Tondera
Head of Biology,
Pantherna Therapeutics
David Jenkinson
Head of Childhood Cancer Translational Challenge,
LifeArc
David Dexter
Research Director,
Parkinson's UK
David Gnutt
Vice President, Complex In Vitro Lead, RED Cardiovascular, Renal and Immunology, ,
Bayer
Davide Gianni
Senior Director,
AstraZeneca
Delphine Heenen
Kicker in Chief Managing Director,
KickCancer
Diana Knapp-Bühle
Associate Director and DMPK Lead,
Merck Healthcare KGaA
Eric Lorent
Senior Scientist,
Sanofi
Eva Aparicio
Product Owner,
Roche
Fabrizio Dissegna
Formulator,
Chiesi
Farshad Ramazani
Senior Expert Science & Technology ,
Novartis
Florian Ries
Senior Scientist,
AbbVie
Gergely Toth
Chief Executive & Scientific Officer, Founder,
Cantabio Pharmaceuticals
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Heena Khatter
Principal Scientist,
Roche
Ian Roberts
Senior Director, Digital Biology,
Healx
Iris Valtingojer
Sanofi Childhood Cancer R&D CSR Lead,
Sanofi
Jack Doolan
Principal Scientist,
GSK
James Love
Vice President, Cross Modalities Workflows,
Novo Nordisk
James Connell
Scientific Director - Translational Matrix Group,
LifeArc
Jens Twellmeyer
Associate Director Science & Technology,
Novartis
Jens Frauenfeld
Chief Executive Officer,
Salipro Biotech
Joao Seixas
CEO,
TargTex
Johanna Roostalu
Director, Therapeutics, Venture Creation,
BioInnovation Institute
Jonathan Hopper
Vice President, Platforms & Founder,
OMass Therapeutics
Jörg Berghausen
Associate Director,
Novartis
Jose-Carlos Gomez-Tamayo
Senior Scientist II,
Janssen Pharmaceutical Companies of Johnson & Johnson
Juan-Carlos Sanchez
Partner,
Woxsen University
Kamalinder Singh
Professor of Pharmaceutical Technology & Drug Delivery,
University of Central Lancashire
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Katja Petkau Milroy
Formulation Scientiest,
Microsol
Kelly Zalocusky
Senior Director of Computational Biology, Neuroscience ,
Recursion Pharmaceuticals
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Konstantinos Gkatzis
Head,
Ksilink
Kristina Levan
Business Developer,
Business Region Gothenburg
Krisztian Kaszas
Principal Scientist,
Johnson & Johnson
Lars van der Veen
Chief Scientific Officer,
ionctura
Laura Gasparini
Director -Tau pathobiology,
AbbVie
Lene Gerlach
Venture Partner; Founder & Chairperson,
Hadean Ventures; Women in Life Science Denmark
Lubor Gaal
Chief Financial Officer & Chief Business Officer,
Circio
Maeve Caldwell
Professor in Neuroscience, Physiology,
Trinity College Dublin
Manuela Cerina
Scientific Director of Neurodegeneration,
LifeArc
Marcos Costa
Principal Scientist,
Roche
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Marie-Christine Pardon
Assistant Professor in Translational Neuroscience,
University of Nottingham
Marius Lutz
Scientist, Process Chemistry,
Hoffmann La Roche Ltd
Mark Chiu
President & Chief Scientific Officer,
Tavotek BioTherapeutics
Markus Hierl
Principal Associate,
Hoffmann La Roche Ltd
Martinus Capelle
Distinguished Scientist II,
Johnson & Johnson Innovative Medicine
Meike Harms
Lead Scientist,
Merck
Meiling Li
Principal Scientist,
Roche
Michael Johnson
Professor of Neurology and Genomic Medicine,
Imperial College London
Miroslav Cik
Senior Principal Research Scientist,
Abbvie
Moein Moghimi
Professor of Nanomedicine and Pharmaceutics,
School of Pharmacy at Newcastle University
Naisha Shah
Vice President of Data Science,
BioAge Labs
Peng Leong
CBO and Head of Brain Aging,
Bioage labs
Phil Noble
Head of Single B Cell Antibody Discovery,
UCB Pharma
Philip Hewitt
Global Head of Early Investigative Toxicology,
Merck
Rainer Wilcken
Senior Director, Computational Chemistry,
Flare Therapeutics Inc
Ramesh Kashi
Former Senior Scientific Director,
Bristol Myers Squibb
Rick Ewing
Vice President, Head of Chemistry,
Rapafusyn Pharmaceuticals
Roderick Beijersbergen
Head of NKI Genomics Core Facility & Professor of Functional Genomics,
The Netherlands Cancer Institute & University of Amsterdam
Sabine Kuratli
CMC Lead,
CEPI
Sagar Chandekar
Senior Medical Director, Alzheimer's Disease,
Novo Nordisk
Sam Daems
Researcher, I3h (ULB) & Portfolio Principal,
Waterland Private Equity
Sandor Batkai
Life Science Consultant, Former, Head of Medical Research and Intelligence,
Formerly Cardior Pharmaceuticals
Sarah Jolly
Principal Scientist,
LifeArc
Simone Hornemann
Director UZH CRISPR Screening Hub,
University of Zurich
Sophie Janbon
Director,
AstraZeneca
Steen Krogsgaard
Scientific Automation Director,
Novo Nordisk
Stefan Schiesser
Director of Medicinal Chemistry,
AstraZeneca
Stefano Romanelli
Senior Government Affairs Manager,
EUCOPE
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Supriyadi Hafiz
Senior Scientist,
Merck
Suruchi Vishwasrao
Senior Scientist,
Merck Life Science Pvt. Ltd.
Sven Verguts
Associate Director, Emerging Biotech & ATMPs,
Merck
Tamara Maes
Former Chief Scientific Officer & Founder,
Oryzon Genomics
Tanvir Tabish
Director,
Astrazeneca
Thanneer Malai Perumal
Senior Principal Scientist,
Hoffmann La Roche Ltd
Tjasa Vrlinic
Principal Investigator,
Medincell
Tom Kissling
pRED Automation Partner & Director at SiLA,
F. Hoffmann-La Roche AG
Tomasz Ratajczak
Formulation Expert,
Polpharma
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trond Ulven
Professor,
Copenhagen University
Valentina Romeo
Principal Scientist & Group Leader,
Roche
Vik Reebye
Head of Academic Partnerships ,
MiNA Therapeutics Ltd
Virginia Ballotta
New Ventures Manager,
BaseLaunch
Vladimir Talibov
Associate Principal Scientist,
Sprint Bioscience
Xavier Garrabou
Director of Operations,
Vivtex
Yi Sun
Associate Professor,
Technical University of Denmark
Zeeshan Ahmad
Reader in Pharmaceutics and Drug Delivery,
University of Manchester
Zhi Yao
Principal Scientist,
LifeArc
Zhizhou Fang
Associate Scientific Director,
Merck Healthcare KGaA
Zoran Rankovic
Professor of Chemical Biology & Director, Centre for Protein Degradation,
The Institute of Cancer Research

Interested in Sponsoring NextGen Omics & Spatial Biology US 2025?

Become a driving force in accelerating the next generation of multi-omics-based treatments. NextGen Omics & Spatial Biology US offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of genomic medicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

Interested in Discovery & Development Europe 2026?